Format

Send to

Choose Destination
See comment in PubMed Commons below
PLoS One. 2012;7(9):e45290. doi: 10.1371/journal.pone.0045290. Epub 2012 Sep 12.

LAPTM4B allele *2 is a marker of poor prognosis for gallbladder carcinoma.

Author information

1
Department of Interventional Radiology and Vascular Surgery, Peking University Third Hospital, Beijing, China.

Abstract

BACKGROUND:

Lysosomal protein transmembrane 4 beta (LAPTM4B) is a novel cancer-related gene which has two alleles designated LAPTM4B*1 and LAPTM4B*2. In this study we investigated the correlation of LAPTM4B genotype with prognosis and clinicopathologic features in patients who had undergone curative resection for gallbladder carcinoma (GBC).

METHODOLOGY/PRINCIPAL FINDINGS:

PCR assay was performed to determine the LAPTM4B genotype in 85 patients. The correlation of LAPTM4B genotype with clinicopathologic parameters was assessed with the Chi-squared test. Differences in patient survival were determined by the Kaplan-Meier method. Multivariate analysis of prognostic factors was carried out with Cox regression analysis. Patients with LAPTM4B *2 had both significantly shorter overall survival (OS) and shorter disease-free survival (DFS) (both P<0.001). Multivariate analysis showed that LAPTM4B genotype is a prognostic factor for OS and DFS (both P<0.001).

CONCLUSIONS/SIGNIFICANCE:

LAPTM4B allele *2 is a risk factor associated with poor prognosis in patients with resected GBC, and LAPTM4B status may be therefore be useful preoperatively as an adjunct in evaluation of the operability of GBC.

PMID:
22984631
PMCID:
PMC3440336
DOI:
10.1371/journal.pone.0045290
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Public Library of Science Icon for PubMed Central
    Loading ...
    Support Center